alexa Sheldon Cooper | OMICS International
ISSN: 2167-7921

Journal of Arthritis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Sheldon Cooper

Sheldon Cooper Sheldon Cooper
Professor of Medicine
Rheumatology Department of Medicine
University of Vermont, USA

Biography

Dr. Sheldon M. Cooper graduated from the New York University School of Medicine in 1967. He works in Burlington, VT and specializes in Rheumatology. Dr. Cooper is affiliated with Central Vermont Medical Center, Copley Hospital and UVM Medical Center Fanny Allen Campus.

Research Interest

Dr. Cooper’s research is focused on understanding the pathogenic mechanisms involved in rheumatoid arthritis, other types of inflammatory arthritis and osteoarthritis. Using this information, new therapeutic agents are developed and tested to determine both their clinical efficacy and their effect upon pathogenic pathways that result in inflammation and/or joint damage. Examples of this strategy are the studies that showed minocycline to be an effective drug for rheumatoid arthritis. Minocycline is an antibiotic that also inhibits the inflammatory response and the enzymatic processes that degrade cartilage and connective tissue. This has provided the rationale for studying whether minocycline, or other tetracycline antibiotics, can slow the progression of osteoarthritis.It has been established that biologic agents that inhibit tumor necrosis factor a (TNFa ) are remarkably effective in the treatment of rheumatoid arthritis. However, it is not known what cellular mechanisms and signaling pathways are influenced by anti-TNFa agents. Clinical research and in vitro studies are in progress to determine what changes occur in patients treated with anti-TNFa drugs, with emphasis on the p38 MAP kinase.

Publications

Global Speakers in the subject

Global Experts in the subject

Top